The launch comes about six months after the company launched its new CryoSphere+ cryoablation probe for the CryoIce platform.
CryoSphere Max features a larger ball tip designed to optimize Cryo Nerve Block therapy (CryoNB). The new probe reduces freeze times by 50% when compared to AtriCure’s first-generation CryoSphere probe. It reduces freeze times by more than 30% when compared to the CryoSphere+.
AtriCure says the CryoSphere Max device reduces the recommended ablation time by 50% per targeted nerve to 60 seconds. This next-generation device features insulation, nitrous oxide gas utilization, tactile tissue feedback and real-time temperature monitoring upgrades.
The company’s CryoNB therapy utilizes the CryoIce platform to freeze targeted intercostal nerves, temporarily blocking pain along peripheral nerve pathways. Physicians use CryoNB as part of their multimodal strategy to provide post-operative pain relief for several months after surgery.
“Every second matters in patient care, and the CryoSphere Max optimizes efficiency for patients and surgeons,” said Michael Carrel, president and CEO at AtriCure. “Strengthening our groundbreaking platform of devices for cryo nerve block therapy underscores AtriCure’s commitment to enhancing surgeons’ procedural experience and pursuing better outcomes for patients.”